ELAB Key Statistics, Chart & Performance
The current stock price of ELAB is 5.28 USD. In the past month the price decreased by -9.59%. In the past year, price decreased by -89.49%.
ELAB Latest News, Press Relases and Analysis
ELAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EL | ESTEE LAUDER COMPANIES-CL A | 55.77 | 33.77B | ||
| KVUE | KENVUE INC | 16.09 | 33.05B | ||
| ELF | ELF BEAUTY INC | 24.35 | 4.27B | ||
| BRBR | BELLRING BRANDS INC | 14.1 | 3.66B | ||
| COTY | COTY INC-CL A | 17.37 | 2.89B | ||
| IPAR | INTERPARFUMS INC | 15.44 | 2.60B | ||
| EPC | EDGEWELL PERSONAL CARE CO | 7.02 | 828.38M | ||
| OLPX | OLAPLEX HOLDINGS INC | 14 | 747.13M | ||
| NUS | NU SKIN ENTERPRISES INC - A | 7.54 | 515.29M | ||
| USNA | USANA HEALTH SCIENCES INC | 10.22 | 365.95M | ||
| NATR | NATURES SUNSHINE PRODS INC | 21.73 | 360.39M | ||
| HNST | HONEST CO INC/THE | 44.83 | 299.32M |
Related stock screener links
About ELAB
Company Profile
PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. The company is headquartered in Newport Beach, California and currently employs 2 full-time employees. The company went IPO on 2023-11-21. The Company’s portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. PMGC Research Inc. is a research and development subsidiary of the Company, which is focused on advancing the frontiers of scientific discovery. PMGC Capital LLC is a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
Company Info
PMGC HOLDINGS INC
120 Newport Center Drive, Ste 250
Newport Beach CALIFORNIA US
Employees: 2
Phone: 18884454886
PMGC HOLDINGS INC / ELAB FAQ
Can you describe the business of PMGC HOLDINGS INC?
PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. The company is headquartered in Newport Beach, California and currently employs 2 full-time employees. The company went IPO on 2023-11-21. The Company’s portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. PMGC Research Inc. is a research and development subsidiary of the Company, which is focused on advancing the frontiers of scientific discovery. PMGC Capital LLC is a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
Can you provide the latest stock price for PMGC HOLDINGS INC?
The current stock price of ELAB is 5.28 USD. The price increased by 0.76% in the last trading session.
Does PMGC HOLDINGS INC pay dividends?
ELAB does not pay a dividend.
How is the ChartMill rating for PMGC HOLDINGS INC?
ELAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of ELAB stock?
PMGC HOLDINGS INC (ELAB) has a market capitalization of 2.22M USD. This makes ELAB a Nano Cap stock.
What is the outstanding short interest for PMGC HOLDINGS INC?
The outstanding short interest for PMGC HOLDINGS INC (ELAB) is 28.72% of its float.
ELAB Technical Analysis
ELAB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ELAB. ELAB has a great financial health rating, but its profitability evaluates not so good.
ELAB Financial Highlights
Over the last trailing twelve months ELAB reported a non-GAAP Earnings per Share(EPS) of -320.19. The EPS increased by 7.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.45% | ||
| ROE | -93.79% | ||
| Debt/Equity | 0 |